This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Arch Ophthalmol. 1999;117:1088-1089.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Hydroxyapatite (HA) orbital spheres are the most commonly used implants after primary enucleations.¹ The wide acceptance of HA implants is due to its high biocompatibility and optimal pore size, which permits host fibrovascular ingrowth. Rapid integration of the implant into the orbital soft tissues offers many potential advantages over nonporous implants, including diminished risk of infection, resistance to implant migration, and enhanced motility with implant peg-prosthesis coupling. We are aware of only 2 histopathologic case reports detailing the degree of host fibrovascularization of a HA sphere (removed because of an orbital malignant neoplasm and not an implant infection) within the first few months after placement of an implant in a human orbit.^2-3 Shields et al² reported approximately 3 mm of fibrovascular ingrowth at the sites of precut scleral windows in a 20-mm, scleral-wrapped, HA sphere removed 4 weeks after implantation in a 69-year-old man. Similarly, in a 20-mm, scleral-wrapped, HA . . . [Full Text of this Article]

Report of a Case.


Comment.
Corresponding author: David R. Jordan, MD, 340 McLeod St, Suite 104, Ottawa, Ontario, Canada K2P 1A4.